PULM HTN 4 RRTs: Pulmonary Pharmacology and IPV Delivery Systems – Current Challenges and Unresolved Issues

Published on Author admin@healthmatterscme.com

HMC_16-638_PH-RRTs_2798x395

Program Overview

  • Breakfast: 6:30 AM – 7:00 AM
  • Symposium: 7:00 AM – 8:00 AM

Pulmonary hypertension (Pulm HTN) can be characterized histopathologically by vasoconstriction, vascular proliferation, and remodeling and narrowing or thrombosis of small pulmonary arteries. If left untreated, these pathological changes result in a progressive rise in pulmonary artery pressure and pulmonary vascular resistance, which eventually leads to right ventricular failure and premature death. Pulm HTN is a condition that RRTs see and treat throughout their professional careers in patients with chronic lung disease. The primary purpose of this activity is to improve the knowledge and competence among RRTs and other health care providers regarding the appropriate management of Pulm HTN, specifically the evidence-based use of inhaled pulmonary vasodilators, including inhaled nitric oxide (iNO). Inhaled pulmonary vasodilators play an important role in treating Pulm HTN, but the administration of these agents should be managed by RRTs and other HCPs qualified by education and experience in their use. This symposium will address the pharmacology of inhaled pulmonary vasodilators and the appropriate use, efficacy, and safety of inhaled vasodilator therapy in the clinical setting. Expert RRT faculty will use a didactic format with audience interaction through Q&A to engage participants in current knowledge and best practices for RRTs in the assessment and management of Pulm HTN.

Target Audience

This activity has been designed to meet the educational needs of Physicians and Respiratory Therapists who treat patients with Pulm HTN.

 

Learning Objectives

After completing this activity, the participant should be better able to:

  • Diagnose Pulm HTN based on the WHO classification system
  • Define pathophysiologic mechanisms of Pulm HTN and the role of inhaled pulmonary vasodilators for the treatment of patients presenting with this condition
  • Recommend optimal inhaled pulmonary vasodilator therapy based on the pharmacology, safety, and efficacy of individual agents for patients with Pulm HTN who are candidates for this intervention
  • Implement inhaled delivery of pulmonary vasodilator therapy for Pulm HTN based on differences among specific agents
  • Approach with appropriate caution the use of aerosolized pulmonary dilating agents not formulated or indicated for use by inhalation

 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and HealthmattersCME.  Global is accredited by the ACCME to provide continuing medical education for physicians.

This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.

 

Physician Credit Designation

Global Education Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Credit Designation – AARC

This program has been approved for a maximum of 1.0 contact hours Continuing Respiratory Care Education (CRCE) credit by the American Association for Respiratory Care, 9425 N. MacArthur Blvd., Suite 100, Irving, TX 75063.

Course # 147280000

 

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest, they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

 

Americans with Disabilities Act

Event staff will be glad to assist you with any special needs (physical, dietary, etc). Please contact Melissa Nocera prior to the live event at 646-674-1820.

 

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com

Schedule

  • Breakfast:           6:30 AM – 7:00 AM
  • Symposium:       7:00 AM – 8:00 AM

 

Scientific Program

  • Welcome and Introduction
  • Pulm HTN Treatment Modalities: Pulmonary Pharmacology, Safety, and Efficacy
  • Pulm HTN Treatment Delivery Systems: Current Challenges and Unresolved Issues
  • Audience Q&A
  • Summary and Conclusions

Program Co-Chairs

Richard D. Branson, MSC, RRT, FAARC, FCCM
Division of Trauma and Critical Care
Department of Surgery
Associate Professor of Surgery
University of Cincinnati Medical Center
Cincinnati, OH

 

Garry W. Kauffman, RRT, FAARC, MPA, FACHE
Director, Respiratory Care Services
Wake Forest University Baptist Health Center
Winston-Salem, NC

Contact Information
Phone: 646-674-9547

THERE IS NO FEE FOR THIS EVENT.

Online Registration

Location
Grand Hyatt San Antonio
600 East Market Street
San Antonio TX 78205


(view map)

This event is fully booked.